Novartis Readies Sales Force For Galvus Ramp-Up In China; Abbott Improves Margin For Nutritionals – Emerging Market Earnings Roundup (Part 1)
This article was originally published in PharmAsia News
Novartis calls 2012 its most challenging year. Abbott projects foreign exchange swings to lead to overall flat revenue growth. Yet both companies plan to offset losses through growth in emerging markets.